BSH 2022 | An overview of current and future clinical trials in amyloidosis

We’ve now got a very active trials portfolio in amyloidosis, which is quite a change from a few years ago where we struggled to have clinical trials. We have got three trials with drugs which can remove amyloid fibril protein, CAEL-101, for patients with advanced cardiac amyloidosis. We’ve got two trials which are for patients with moderately advanced and very advanced cardiac amyloidosis. We have got AFFIRM, which is a trial of NEOD001 for also patients with advanced cardiac amyloidosis.

We are about to open a trial called AQUARIUS, which is a trial of dara VCD, but compared with single agent daratumumab followed by delayed VCD, because we think some of the toxicity comes from the velcade dexamethasone in patients with specifically, cardiac amyloidosis. That trial is also trying to recruit patients from ethnic minorities who are underrepresented in the trial.

We then have the RELAPSE trial of belantamab, sponsored by EMN, for patients with relapsed/refractory amyloidosis. Then we will probably have two trials opening in the very near future for new PET agents, which will be diagnostic agents, hopefully commercially available for amyloid diagnosis.